The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis (CONDUCT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03178669 |
Recruitment Status :
Active, not recruiting
First Posted : June 7, 2017
Last Update Posted : August 6, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ulcerative Colitis | Drug: cobitolimod Drug: Placebo | Phase 2 |
This is a Phase 2b study in patients with moderate to severe active ulcerative colitis. Patients will either receive cobitolimod dose A, B or C at two occasions or dose B or placebo at four occasions. To ensure blindness patients receiving active treatment at two occasions will receive placebo at the other two occasions. Blood, stool, and tissue samples will be collected at various time points throughout the study to evaluate safety and efficacy.
Duration of participation for patients will be approximately 12 weeks.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 213 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients |
Actual Study Start Date : | June 21, 2017 |
Estimated Primary Completion Date : | September 2019 |
Estimated Study Completion Date : | September 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Cobitolimod Dose 31 mg x 2
Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
|
Drug: cobitolimod
Rectal administration
Other Name: Kappaproct |
Experimental: Cobitolimod Dose 125 mg x 2
Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
|
Drug: cobitolimod
Rectal administration
Other Name: Kappaproct |
Experimental: Cobitolimod Dose 250 mg x 2
Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
|
Drug: cobitolimod
Rectal administration
Other Name: Kappaproct |
Experimental: Cobitolimod Dose 125 mg x 4
Dose 125 mg of cobitolimod, at 4 occasions
|
Drug: cobitolimod
Rectal administration
Other Name: Kappaproct |
Placebo Comparator: Placebo
Placebo at four occasions
|
Drug: Placebo
Solution manufactured to mimic cobitolimod
Other Name: Placebo (for cobitolimod) |
- Clinical Remission [ Time Frame: 6 weeks after first treatment ]defined by Modified Mayo sub scores, i) rectal bleeding of 0, ii) stool frequency of 0 or 1 (with at least one point decrease from Baseline, and iii) endoscopy score of 0 or 1 (excluding friability)
- Symptomatic Remission [ Time Frame: Week 4 and Week 6 ]defined by the Mayo sub scores, i) rectal bleeding of 0, ii) stool frequency of 0 or 1 (with at least one point decrease from Baseline, (patient reported outcome) [PRO2]
- Abscence of rectal bleeding [ Time Frame: Week 4 and Week 6 ]defined by the Mayo sub score rectal bleeding of 0
- Normal or enhanced stool frequency [ Time Frame: Week 4 and Week 6 ]defined by the Mayo sub score stool frequency of 0 or 1 (with at least one point decrease from Baseline)
- Endoscopic Remission [ Time Frame: Week 6 ]defined by the Modified Mayo endoscopic sub score of 0 or 1 (excluding friability)
- Histological Remission [ Time Frame: Week 6 ]defined by the Nancy histological index
- Histological Response [ Time Frame: Week 6 ]defined by the Nancy histological index score
- Modified Clinical Remission [ Time Frame: Week 6 ]defined by the Modified Mayo score ≤ 2 and sub scores, i) rectal bleeding of 0, ii) stool frequency of 0 or 1 (with at least one point decrease from Baseline), iii) endoscopy score of 0 or 1 (excluding friability ) and iiii) physician´s global assessment (PGA) of 0 or 1
- Clinical Response [ Time Frame: Week 6 ]defined as clinical remission or a three point and ≥ 30% decrease from Baseline.
- Change in faecal calprotectin [ Time Frame: Week 1,2, 3 and 6 ]defined as a mean change compared to Baseline
- Change in the inflammatory bowel disease questionnaire (IBDQ) [ Time Frame: Week 6 ]defined as mean change compared to Baseline

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years old
- Established diagnosis of UC
- Moderately to severely active left sided UC assessed by central reading
- Current oral 5-ASA/SP use or a history of oral 5-ASA/SP use
- Current GCS use or history of GCS dependency, refractory, or intolerance
-
Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following agents:
- Immunomodulators
- TNF-α inhibitors and/or anti-integrins
Exclusion Criteria:
- Suspicion of differential diagnosis
- Acute fulminant UC and/or signs of systemic toxicity
- UC limited to the rectum (disease which extend <15 cm above the anal verge)
- History of malignancy
- History or presence of any clinically significant disorder
- Concomitant treatment with cyclosporine, methotrexate, tacrolimus, TNF-α inhibitors, anti-integrins or similar immunosuppressants and immunomodulators
- Treatment with rectal GCS, 5-ASA/SP or tacrolimus
- Long term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs)
- Serious active infection
- Gastrointestinal infections
- Currently receiving parenteral nutrition or blood transfusions
- Females who are lactating or have a positive serum pregnancy test
- Women of childbearing potential not using reliable contraceptive methods
- Concurrent participation in another clinical study
- Previous exposure to cobitolimod

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03178669

Principal Investigator: | Raja Atreya | Friedrich-Alexander University Erlangen-Nuremberg |
Responsible Party: | InDex Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT03178669 History of Changes |
Other Study ID Numbers: |
CSUC-01/16 2016-004217-26 ( EudraCT Number ) |
First Posted: | June 7, 2017 Key Record Dates |
Last Update Posted: | August 6, 2019 |
Last Verified: | August 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Colitis, Ulcerative Gastrointestinal Diseases Inflammatory Bowel Disease Immunomodulator Therapy Glucocorticoids |
Anti-Inflammatory Agents Therapeutic uses Kappaproct IDX0150 DIMS0150 |
Colitis Colitis, Ulcerative Ulcer Gastroenteritis Gastrointestinal Diseases |
Digestive System Diseases Colonic Diseases Intestinal Diseases Pathologic Processes Inflammatory Bowel Diseases |